Nuvectis Pharma, Inc. (NVCT) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Nuvectis Pharma, Inc. (NVCT) Earnings Overview
As of June 30, 2026, Nuvectis Pharma, Inc. (NVCT) reported trailing twelve-month net income of -$27M, reflecting -18.9% year-over-year growth. The company earned $-1.16 per diluted share over the past four quarters.
Looking at the long-term picture, NVCT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$10,000 in fiscal 2020.
Nuvectis Pharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), KYMR (-$315M net income, -794.4% margin), TNGX (-$107M net income, -162.9% margin), NVCT has comparable earnings metrics. Compare NVCT vs IMVT →
NVCT Earnings vs Peers
Earnings metrics vs comparable public companies
NVCT Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$26M | -39.2% | -$28M | $-1.32 | - | - |
| 2024 | -$19M | +14.6% | -$20M | $-1.11 | - | - |
| 2023 | -$22M | -16.6% | -$23M | $-1.43 | - | - |
| 2022 | -$19M | -48.1% | -$19M | $-1.51 | - | - |
| 2021 | -$13M | -128800.0% | -$13M | $-1.09 | - | - |
| 2020 | $-10,000 | - | $-10,000 | $-0.00 | - | - |
Download Data
Export NVCT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NVCT — Frequently Asked Questions
Quick answers to the most common questions about buying NVCT stock.
What is NVCT earnings per share (EPS)?
NVCT trailing twelve-month (TTM) diluted EPS is $-1.16, reflecting -18.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Nuvectis Pharma, Inc.'s net income?
Nuvectis Pharma, Inc. (NVCT) trailing twelve-month net income is $-27M as of 2025. Earnings declined -18.9% year-over-year.
Is NVCT profitable?
NVCT is not currently profitable on a TTM basis, reporting a net loss of $-27M. Net margin is N/A. Investors should monitor for a return to profitability.
What is NVCT's earnings growth rate?
NVCT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are NVCT's profit margins?
Nuvectis Pharma, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -188.0%.
Is NVCT growing earnings?
NVCT earnings are declining — EPS fell -18.9% year-over-year. TTM net income dropped to $-27M. This contrasts with the 5-year CAGR of N/A.
What was NVCT's best earnings year?
Nuvectis Pharma, Inc.'s highest annual net income on record is $-10000.00, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were NVCT's earnings last quarter?
NVCT's most recent reported quarter was Q1 2026. Net income was $-6M with diluted EPS of $-0.26. For a full breakdown of all quarters, see the quarterly earnings table on this page.